{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:44:26Z","timestamp":1782787466798,"version":"3.54.5"},"reference-count":51,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Background: This review aims to provide a comprehensive and practical overview of the evolving role of autologous transplantation in leukaemias, a strategy that was once largely abandoned but has recently regained interest in selected clinical settings. Methods: We reviewed the historical development of autologous transplantation in acute leukaemias, including the early period during which autologous transplantation was considered inferior to allogeneic approaches because of limited graft purification techniques and the inability to induce effective graft-versus-leukaemia (GVL)-like immune responses. We further summarise more recent experimental strategies aimed at improving stem cell purification and enhancing anti-leukaemic immune activity in autologous settings. In addition, we discuss how advances in measurable residual disease (MRD) assessment and molecular risk stratification have contributed to the renewed interest in autologous transplantation in selected subgroups of leukaemia patients. Results: This review identifies clinical situations in which autologous transplantation remains an important therapeutic option, including plasma cell leukaemia, where it continues to represent a standard first-line approach. We also discuss well-defined patient subgroups, particularly selected AML subtypes with intermediate-risk molecular profiles and acute promyelocytic leukaemia (APL) in second remission, in which outcomes following autologous transplantation may be comparable to, or occasionally superior to, those achieved with allogeneic transplantation. In contrast, autologous transplantation currently plays only a limited role in diseases such as chronic lymphocytic leukaemia (CLL) and chronic myeloid leukaemia (CML). Although attempts to induce potent anti-leukaemic immune effects in autologous settings have so far shown limited clinical efficacy, several emerging strategies appear promising and may further expand the role of autologous transplantation, particularly in elderly or frail patients. Discussion: Overall, current molecular and MRD-based risk stratification strategies, together with emerging immunological and graft-manipulation approaches, may redefine the role of autologous transplantation as a personalised therapeutic option in selected subgroups of leukaemia patients.<\/jats:p>","DOI":"10.3390\/hematolrep18040044","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:55:11Z","timestamp":1782780911000},"page":"44","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of Autologous Haematopoietic Transplantation in Leukaemias: When to Consider It in 2026"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0487-8200","authenticated-orcid":false,"given":"Mikl\u00f3s","family":"Udvardy","sequence":"first","affiliation":[{"name":"Division of Haematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Member of ERN-EuroBlood-NET, H-4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lajos","family":"Gergely","sequence":"additional","affiliation":[{"name":"Division of Haematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Member of ERN-EuroBlood-NET, H-4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1343-6017","authenticated-orcid":false,"given":"R\u00f3bert","family":"Sz\u00e1sz","sequence":"additional","affiliation":[{"name":"Division of Haematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Member of ERN-EuroBlood-NET, H-4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyula","family":"Rem\u00e9nyi","sequence":"additional","affiliation":[{"name":"Division of Haematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Member of ERN-EuroBlood-NET, H-4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0453-1709","authenticated-orcid":false,"given":"L\u00e1szl\u00f3 Imre","family":"Pincz\u00e9s","sequence":"additional","affiliation":[{"name":"Division of Haematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Member of ERN-EuroBlood-NET, H-4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1rp\u00e1d","family":"Ill\u00e9s","sequence":"additional","affiliation":[{"name":"Division of Haematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Member of ERN-EuroBlood-NET, H-4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/j.seminhematol.2016.01.003","article-title":"Autologous stem cell transplantation versus alternative allogeneic donor transplants in adult acute leukaemias","volume":"53","year":"2016","journal-title":"Semin. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(97)09214-3","article-title":"Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: Results of MRC AML 10 trial. UK Medical Research Council Adult and Children\u2019s Leukaemia Working Parties","volume":"351","author":"Burnett","year":"1998","journal-title":"Lancet"},{"key":"ref_3","first-page":"477","article-title":"Bone marrow transplantation: Current results in leukaemia","volume":"55","author":"Santos","year":"1982","journal-title":"Yale J. Biol. Med."},{"key":"ref_4","first-page":"40","article-title":"Autologous bone marrow transplantation for leukaemia","volume":"20","author":"Stuart","year":"1993","journal-title":"Semin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.bbmt.2019.02.018","article-title":"Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease\/Sinusoidal Obstruction Syndrome","volume":"25","author":"Corbacioglu","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2991\/chi.k.210703.002","article-title":"History and Development of Autologous Stem Cell Transplantation for Acute Myeloid Leukaemia","volume":"3","author":"Gorin","year":"2021","journal-title":"Clin. Hematol. Int."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Sweeney, C., and Vyas, P. (2019). The Graft-Versus-Leukaemia Effect in AML. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01217"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1089\/scd.1.1995.4.261","article-title":"Introducing graft-versus-leukaemia into autologous stem cell transplantation","volume":"4","author":"Klingemann","year":"1995","journal-title":"J. Hematother."},{"key":"ref_9","first-page":"5385972","article-title":"Autologous Graft-versus-Tumour Effect: Reality or Fiction?","volume":"2016","author":"Porrata","year":"2016","journal-title":"Adv. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cytogfr.2010.02.010","article-title":"Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus","volume":"21","author":"Rahman","year":"2010","journal-title":"Cytokine Growth Factor. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e24500","DOI":"10.4161\/onci.24500","article-title":"Strategies for purging CD96+ stem cells in vitro and in vivo: New avenues for autologous stem cell transplantation in acute myeloid leukaemia","volume":"2","author":"Staudinger","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.omtm.2021.04.004","article-title":"Induced dendritic cells co-expressing GM-CSF\/IFN-\u03b1\/tWT1 priming T and B cells and automated manufacturing to boost GvL","volume":"21","author":"Domning","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1182\/bloodadvances.2023010477","article-title":"Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplant","volume":"7","author":"Solomon","year":"2023","journal-title":"Blood Adv."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jtct.2025.05.014","article-title":"Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy\u2014A Report from the CIBMTR","volume":"31","author":"Spellman","year":"2025","journal-title":"Transplant. Cell Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/gcc.22756","article-title":"Clonal hematopoiesis and preleukaemia: Genetics, biology, and clinical implications","volume":"58","author":"Hartmann","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.bbmt.2019.07.013","article-title":"Allogeneic Stem Cell Transplantation in Therapy-Related Myelodysplasia after Autologous Transplantation for Lymphoma: A Retrospective Study of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy","volume":"25","author":"Albornoz","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1111\/trf.14895","article-title":"Iron overload is correlated with impaired autologous stem cell mobilisation and survival in acute myeloid leukaemia","volume":"58","author":"Alva","year":"2018","journal-title":"Transfusion"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1002\/sctm.21-0176","article-title":"Optimising autologous hematopoietic stem cell transplantation for acute leukaemia","volume":"10","author":"Pang","year":"2021","journal-title":"Stem Cells Transl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s12185-019-02759-y","article-title":"Autologous hematopoietic cell transplantation for acute myeloid leukaemia in adults: 25 years of experience in Japan","volume":"111","author":"Tanada","year":"2020","journal-title":"Int. J. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1053\/j.seminhematol.2019.01.001","article-title":"Autologous hematopoietic cell transplantation for AML in first remission\u2014An abandoned practice or promising approach?","volume":"56","author":"Yeshurun","year":"2019","journal-title":"Semin. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12935-025-04118-w","article-title":"Interferon-\u03b1 enhances NK cell function to counteract autologous platelet-mediated tumour immune evasion","volume":"26","author":"Wang","year":"2026","journal-title":"Cancer Cell Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s13046-025-03558-6","article-title":"Challenges and opportunities of human iPSC-derived NK as \u201cOff-the-shelf\u201d cellular therapies","volume":"44","author":"Romanini","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Stein, J., Anand, P., Abdulmajid, J., Hartz, A., Unterfrauner, M., Feng, X., Schmieder, N., Kruk, L., Bojko, P., and Schmohl, J. (2025). Monitoring of (Leukaemia-Specific) Immune Cells in Stages, Treatment Groups and in the Course of Disease and Therapy Contributes to Qualifying Antileukemic Potential and Survival in Patients with AML. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262110336"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.5045\/br.2022.2022033","article-title":"Update on primary plasma cell leukaemia","volume":"57","author":"Jung","year":"2022","journal-title":"Blood Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3324\/haematol.2009.013334","article-title":"Primary plasma cell leukaemia and autologous stem cell transplantation","volume":"95","author":"Drake","year":"2010","journal-title":"Haematologica"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/j.bbmt.2020.08.035","article-title":"Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukaemia in the Era of Novel Agents","volume":"26","author":"Lemieux","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Xu, Y., He, J., Chen, L., Liu, J., Zhou, M., Chen, B., and Bai, H. (2026). Survival improvement in primary plasma cell leukaemia: A retrospective analysis of novel agent-based regimens and stem cell transplantation. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1727117"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0753-3322(97)86003-9","article-title":"Autologous bone marrow transplantation in chronic lymphocytic leukaemia (CLL)","volume":"50","author":"Mangoni","year":"1996","journal-title":"Biomed. Pharmacother."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Sureda, A., Corbacioglu, S., Greco, R., Kr\u00f6ger, N., and Carreras, E. (2024). Chronic Lymphocytic Leukaemia. The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies, Springer. [8th ed.].","DOI":"10.1007\/978-3-031-44080-9"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6057","DOI":"10.1182\/blood-2011-04-344093","article-title":"Autografting CLL: The game is over!","volume":"117","author":"Montserrat","year":"2011","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1038\/s41375-025-02744-x","article-title":"Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukaemia patients: A propensity score matching analysis from the PETHEMA AML registry","volume":"39","author":"Gil","year":"2025","journal-title":"Leukaemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000495206","article-title":"Autologous Stem Cell Transplantation Is a Viable Postremission Therapy for Intermediate-Risk Acute Myeloid Leukaemia in First Complete Remission in the Absence of a Matched Identical Sibling: A Meta-Analysis","volume":"141","author":"Li","year":"2019","journal-title":"Acta Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.bbmt.2017.01.070","article-title":"Clinical Outcome of Autologous Hematopoietic Cell Transplantation in Adult Patients with Acute Myeloid Leukaemia: Who May Benefit from Autologous Hematopoietic Cell Transplantation?","volume":"23","author":"Yoon","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"311.e1","DOI":"10.1016\/j.jtct.2020.12.029","article-title":"Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients with Intermediate Cytogenetic Risk Acute Myeloid Leukaemia: A PETHEMA Study","volume":"27","author":"Vidriales","year":"2021","journal-title":"Transplant. Cell Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1038\/s41409-019-0762-3","article-title":"Excellent outcome after consolidation with autologous transplantation in patients with core binding factor acute myeloid leukaemia","volume":"55","author":"Sula","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/s41409-023-02070-9","article-title":"Autologous stem cell transplantation in adult patients with intermediate-risk acute myeloid leukaemia in first complete remission and no detectable minimal residual disease. A comparative retrospective study with haploidentical transplants of the Global Committee and the ALWP of the EBMT","volume":"58","author":"Chen","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/cam4.5039","article-title":"Autologous stem cell transplantation (ASCT) for acute myeloid leukaemia in patients in first complete remission after one versus two induction courses: A study from the ALWP of the EBMT","volume":"12","author":"Nagler","year":"2023","journal-title":"Cancer Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"599.e1","DOI":"10.1016\/j.jtct.2024.03.024","article-title":"Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Promyelocytic Leukaemia: Results of a Systematic Review and Meta-Analysis","volume":"30","author":"Mohty","year":"2024","journal-title":"Transplant. Cell Ther."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Costa, A., Gurnari, C., Scalzulli, E., Cicconi, L., Guarnera, L., Carmosino, I., Cerretti, R., Bisegna, M.L., Capria, S., and Minotti, C. (2024). Response Rates and Transplantation Impact in Patients with Relapsed Acute Promyelocytic Leukaemia. Cancers, 16.","DOI":"10.3390\/cancers16183214"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"847.e1","DOI":"10.1016\/j.jtct.2022.09.021","article-title":"Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed Acute Promyelocytic Leukaemia","volume":"28","author":"Yanada","year":"2022","journal-title":"Transplant. Cell Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/bjh.17219","article-title":"Autologous stem cell transplantation finds a place in acute promyelocytic leukaemia","volume":"192","author":"Breccia","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/pbc.21614","article-title":"Mobilisation of PML-RARA negative blood stem cells and salvage with autologous peripheral blood stem cell transplantation in children with relapsed acute promyelocytic leukaemia","volume":"51","author":"Termuhlen","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.bbmt.2014.03.025","article-title":"Autologous is superior to allogeneic hematopoietic cell transplantation for acute promyelocytic leukaemia in second complete remission","volume":"20","author":"Rubinger","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_44","first-page":"2207","article-title":"High rate of durable remissions post autologous stem cell transplantation for core-binding factor acute myeloid leukaemia in second complete remission","volume":"55","author":"Rees","year":"2020","journal-title":"BoneMarrow Transplant."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukaemia: Results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Swoboda, R., Labopin, M., Giebel, S., Maertens, J., Parovichnikova, E., Versluis, J., Pavlu, J., Kopinska, A., Capria, S., and Raida, L. (2025). Autologous stem cell transplantation for adults with Philadelphia-negative acute lymphoblastic leukaemia in first complete remission. A study by the Acute Leukaemia Working Party of the EBMT. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-14126-8"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41409-022-01904-2","article-title":"Autologous versus allogeneic hematopoietic cell transplantation for older patients with acute lymphoblastic leukaemia. An analysis from the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"58","author":"Giebel","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/978-3-642-46836-0_2","article-title":"Autologous stem cell transplantation for chronic myeloid leukaemia","volume":"144","author":"CMLMahon","year":"1998","journal-title":"Recent. Results Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/bmt.2016.258","article-title":"Impact of drug development on the use of stem cell transplantation: A report by the European Society for Blood and Marrow Transplantation (EBMT)","volume":"52","author":"Passweg","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Marcuzzi, A., and Maximova, N. (2023). Editorial: Advances in stem cell therapy: New applications and innovative therapeutic approaches. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1225551"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e113466","DOI":"10.1136\/bmjopen-2025-113466","article-title":"Impact of an early warning system on the outcome of patients with haematological malignancies receiving high-dose chemotherapy with or without haematopoietic cell transplantation: A protocol of the ALHERT cluster randomised trial","volume":"16","author":"Kouatchet","year":"2026","journal-title":"BMJ Open"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/4\/44\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:09:51Z","timestamp":1782785391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/4\/44"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":51,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["hematolrep18040044"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep18040044","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]}}}